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OBJECTIVES We tested the hypothesis that acute intravenous verapamil acutely enhances aerobic exercise
performance in healthy older individuals in association with a combined reduction of
ventricular systolic and arterial vascular stiffnesses.
BACKGROUND Age-related vascular stiffening coupled with systolic ventricular stiffening may limit cardio-
vascular reserve and, thus, exercise performance in aged individuals.
METHODS Nineteen healthy volunteers with mean age 70 6 10 years underwent maximal-effort upright
ergometry tests on two separate days after receiving either 0.15 mg/kg i.v. verapamil or 0.5 N
saline in a double-blind, randomized, crossover study.
RESULTS Baseline vascular stiffness, indexed by arterial pulse-wave velocity (Doppler) and augmenta-
tion index (carotid tonometry) declined with verapamil (25.9 6 2.1% and 231.7 6 12.8%,
respectively, both p , 0.05). Preload-adjusted maximal ventricular power, a surrogate for
ventricular end-systolic stiffness, also declined by 29.5 6 3.6%. Peripheral resistance and
peak filling rate were unchanged. With verapamil, exercise duration prior to the anaerobic
threshold (AT) increased by nearly 50% (260 6 129 to 387 6 176 s) with a corresponding
13.4 6 4.7% rise in oxygen consumption (V˙O2) at that time (both p , 0.01). Total exercise
duration prolonged by 16 6 2.7% (p , 0.05) with no change in maximal V˙O2. Baseline
cardiodepression from verapamil reversed by peak exercise with net increases in stroke volume
and cardiac output (p , 0.05).
CONCLUSIONS Acute intravenous verapamil reduces ventriculovascular stiffening and improves aerobic
exercise performance in healthy aged individuals. This highlights a role for heart-arterial
coupling in modulating exertional capacity in the elderly, suggesting a potentially therapeutic
target for aged individuals with exertional limitations. (J Am Coll Cardiol 1999;33:1602–9)
© 1999 by the American College of Cardiology
Aerobic capacity declines with age (1), with exertional
fatigue and frailty often occurring in the absence of cardiac
or peripheral vascular ischemia (2). Several age-related
cardiovascular changes may contribute to such altered exer-
cise physiology (1). One potentially important factor is
arterial stiffening (3–5), which increases pulsatile and non-
pulsatile components of vascular load (5) imposed on the
heart, resulting in systolic hypertension and enhanced sys-
tolic wave reflections (1,3–5). We recently reported that left
ventricular systolic stiffness (i.e., end-systolic elastance,
[Ees]) also increases with age, matching cardiac function to
the altered arterial load (6). Coupling a stiff heart in systole
with a stiff arterial system impedes the transfer of increased
stroke volume (SV) from heart to artery without concomi-
tant substantial increases in pressure load, which in turn can
feed back to inhibit cardiac ejection. Furthermore, a less stiff
heart and vasculature can better accommodate reduced
end-systolic volumes (ESV), whereas stiffer properties may
contribute to a greater reliance on preload reserve in the
elderly (7,8).
If combined ventricular-vascular stiffening limits exer-
tional tolerance, then agents such as verapamil, which lower
both end-systolic stiffness (9) and arterial stiffness (10),
might improve exercise capacity. In particular, more effec-
tive ventricular-to-vascular interaction could enhance SV
and cardiac output reserve, prolonging aerobic exercise
duration. The present study tested this hypothesis in healthy
elderly subjects.
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METHODS
Control subjects. Twenty-four healthy volunteers aged 50
to 90 years were recruited from the general public. Control
subjects with coronary or peripheral vascular ischemia,
significant valvular regurgitation or stenosis, prior myocar-
dial infarction, atrial fibrillation and those unable to with-
hold vasoactive medications for at least 24 h prior to study
were excluded. Informed consent was obtained from each
subject and the protocol approved by the Joint Committee
on Clinical Investigation of the Johns Hopkins Medical
Institutions. Three control subjects developed significant
asymptomatic electrocardiographic ST segment depression
with regional wall motion abnormalities on radionuclide
ventriculography during exercise, while two subjects failed
to complete the protocol (allergic reaction to verapamil,
failure to return for follow-up). Data are reported from the
remaining 19 subjects, comprised of 10 men and 9 women
with a mean age 67.4 6 10.5 years (range 50–84). Three
individuals had hypertension treated with an angiotensin
converting enzyme inhibitor, angiotensin II receptor
blocker, or alpha1-blocker. No subject was treated with a
Ca21-channel blocker.
Study design. We used a double-blind, randomized,
placebo-controlled crossover design. Verapamil
(0.15 mg/kg) or saline control (0.5 N NaCl-D5W) was
injected i.v. in 5 mL over 5 min. Baseline cardiac and
vascular properties were obtained (detailed below) in the
supine position prior to and 15 min after the infusion.
Maximal effort upright bicycle ergometry was then per-
formed. Cardiac volumes, arterial pressures and several
derived indexes of cardiovascular function were measured
immediately before and during each stage of exercise. Each
control subject returned for a second study one to seven days
later, using the identical protocol but with the alternative
agent.
Vascular measurements. Carotid tonometry, transcutane-
ous Doppler flow velocity and noninvasive calibrated central
arterial pressure assessed arterial vascular properties. Carotid
applanation tonometry was performed with a hand-held
transducer (SPC-350, Millar Instruments, Houston, Texas)
(11). Signals were digitized at 200 Hz, and the ratio of
pressure rise after the midlate systolic inflection to the total
pulse pressure (augmentation index [AI]) (12,13) was de-
termined. The inflection point was identified from zero-
crossing timings of the fourth derivative of the pressure
signal (14). Doppler flow signals (2.0 MHz nonimaging
transducer, CFM 800, Vingmed Sound, Norway) were
measured in the ascending aorta or right carotid artery and
right femoral artery along with simultaneous electrocardio-
gram. The time from the R wave of the QRS complex to the
foot of each flow wave (15,16) was subtracted to yield
propagation time, and aortic pulse wave velocity (PWV) was
the external distance between the suprasternal notch and
right femoral pulse divided by this time.
Noninvasive calibrated central arterial pressures were
measured using an improved version of a previously vali-
dated device (17). This system consisted of a computer-
controlled sphygmomanometric arm cuff with an internal
transducer to measure cuff pressure, dual microphones over
the brachial artery at the antecubital fossa and an electro-
cardiographic monitor. The cuff was inflated above systolic
pressure and then deflated at 2 to 3 mm Hg/beat. During
deflation, Korotkoff sounds were recorded and the time
delay between the ECG-R wave and the Korotkoff sound
determined as a function of cuff pressure. This time delay
combined cardiac electromechanical delay, flow transit time
from aorta to brachial artery and the time for arterial
pressure to exceed cuff pressure. This last component
declined with cuff pressure, so plotting cuff pressure versus
time delay produced the upstroke portion of the arterial
waveform. A prior version of this system employed a
Doppler transducer to signal the onset of brachial flow (17);
however, maintaining persistent flow signals during exercise
was problematic. In contrast, detection of Korotkoff sounds
was less sensitive to exact dual microphone positioning and
was more reliable during exercise.
The effective arterial elastance (Ea) was also determined
as a measure of total vascular load. Both mean and pulsatile
components of arterial impedance are manifest in Ea, and it
has been shown to quantify influences of vascular loading on
heart function in intact patients better than does mean
resistance (18). Effective arterial elastance is equal to the
ratio of end-systolic pressure (Pes) to SV. End-systolic
pressure may be estimated by 0.9zarterial-systolic pressure
(Psys) (18), so that Ea 5 0.9zPsys/SV. Psys was arterial systolic
pressure. Stroke volume was determined from radionuclide
ventriculography.
Cardiac measurements. Gated technetium99m pertechne-
tate radionuclide ventriculography blood pool scans were
obtained in the left anterior oblique orientation at 32
frames/cycle at rest in the supine position before and after
drug administration. Scans were gated at 16 frames/cycle
during exercise. Time-activity curves from identified regions
Abbreviations and Acronyms
AI 5 augmentation index
AT 5 anaerobic threshold
Ea 5 effective arterial elastance
EDV 5 end-diastolic volume
Ees 5 end-systolic elastance
EF 5 ejection fraction
ESV 5 end-systolic volume
Pes 5 end-systolic pressure
PFREDV 5 peak filling rate/EDV
Psys 5 arterial systolic pressure
PWRmax 5 maximal power
PWV 5 pulse wave velocity
SV 5 stroke volume
V˙O2 z 5 maximal oxygen consumption
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of interest were calibrated for ventricular volume using a
count-based method with peripheral blood sampling to
determine counts per mL of a reference volume and with
correction for attenuation of left ventricular counts (19). In
addition to providing ESV, end-diastolic volume (EDV),
SV and ejection fraction (EF), time-activity curves were fit
to a four-term Fourier series that was analytically differen-
tiated to yield flow (20).
Left ventricular power equalled the product of ascending
aortic pressure and ventricular systolic flow. Signals were
adjusted so the onset of flow and the arterial end-diastolic
pressure were synchronous. Maximal power (PWRmax) was
the peak pressure-flow product. Maximal power varies with
preload volume but is relatively insensitive to arterial load
(20,21), and PWRmax/EDV has been shown to be both pre-
and afterload insensitive in normal sized hearts (22). Im-
portantly, changes in preload-adjusted PWRmax correlate
with those of chamber end-systolic stiffness (20) (i.e., Ees),
but unlike Ees, PWRmax can be measured noninvasively
during exercise (22). In the present study, PWRmax/EDV
was used as a surrogate for Ees changes.
Cardiopulmonary exercise testing. Maximal effort upright
bicycle exercise was performed, starting at a 25 W, and
increasing 25 W every three minutes until exhaustion.
Standard 12-lead electrocardiographic monitoring was per-
formed. Breath-by-breath levels of oxygen consumed (V˙O2)
and carbon dioxide produced (V˙CO2) were measured
(CPX, MedGraphics, St. Paul, Minnesota). Maximal oxy-
gen consumption at the anaerobic threshold (AT) (23) was
determined by the V-slope method (24) and peak V˙O2
defined as the mean value over 15 s prior to termination of
exercise. Exercise capacity was assessed by total exercise
duration, time-to-reach AT, V˙O2 at the AT and maximal
V˙O2. Gated blood pool acquisitions were obtained during
the last 2.5 min of each 3-min exercise load, and noninva-
sive central arterial pressures were recorded during the last
minute of each stage.
Statistical analysis. Data are presented as mean 6 SD.
Within subject effects comparing verapamil to saline infu-
sion before and after infusion at rest and during exercise,
between intervention studies and their interaction (i.e.,
different responses between verapamil vs. placebo) were
tested by a repeated measures one-way analysis of variance.
Post-hoc tests between individual means were then per-
formed using Tukey’s test for multiple comparisons. Dif-
ferences of baseline hemodynamics and exercise capacity
between the two studies were compared by Student’s two-
tailed paired t test.
RESULTS
Baseline data and response to verapamil. Table 1 pro-
vides baseline data for each of the two sequential studies.
There were no significant differences in any parameter.
Arterial systolic pressure averaged 140 6 10 mm Hg and
arterial pulse pressure 66.7 6 19.7 mm Hg, consistent with
age-related vascular changes (25).
Figure 1 compares the effects of verapamil with saline
control on resting cardiovascular function. Verapamil low-
ered AI of the carotid pulse, slightly increased LV volumes
and lowered PWRmax. Augmentation index declined from
25 6 1 to 19 6 14% (232 6 13%, p , 0.05), PWV
Table 1. Baseline Cardiovascular Indexes Between Two Study Days
0.5 N Saline Verapamil p Values
Vascular Indices
Psys (mm Hg) 140 6 19 141 6 16 NS
Pdia (mm Hg) 72 6 13 72 6 11 NS
MBP (mm Hg) 95 6 12 95 6 8 NS
TPR (dynezseczcm25) 1,311 6 323 1,276 6 174 NS
AI (%) 23 6 15 25 6 11 NS
PWV (cm/sec) 906 6 248 905 6 192 NS
Ea (mm Hg/mL) 1.41 6 0.28 1.38 6 0.21 NS
Ventricular Indices
EDV (mL) 136 6 20 135 6 19 NS
ESV (mL) 44 6 15 42 6 14 NS
SV (mL) 91 6 15 93 6 13 NS
CO (L/min) 6.0 6 1.3 6.0 6 0.9 NS
EF (%) 68 6 8 69 6 8 NS
PWRmax/EDV (watts/mLz10
2) 5.74 6 1.42 6.03 6 1.19 NS
PFR/EDV (sec21) 2.8 6 0.6 3.0 6 0.7 NS
Heart rate (beats/min) 66 6 12 66 6 11 NS
Data presented are mean value 6 SD.
AI 5 augmentation index; CO 5 cardiac output; Ea 5 effective arterial elastance; EDV 5 end-diastolic volume; ESV 5
end-systolic volume; EF 5 left ventricular ejection fraction; PWRmax 5 maximal ventricular power; MBP 5 mean blood
pressure; PFR 5 peak filling rate; PWV 5 pulse wave velocity; SV 5 stroke volume; Psys 5 systolic blood pressure; TPR 5 total
peripheral resistance.
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declined from 905 6 192 to 847 6 173 cm/sec (25.9 6
2.1%, p , 0.05), and PWRmax/EDV declined from 6.04 6
1.19 to 5.38 6 1.13 watts/mL (29.5 6 3.6%, p , 0.05).
Compared with saline, verapamil also lowered Psys (141 6
16 to 136 6 16 mm Hg) but not mean pressure, Ea (1.38 6
0.21 to 1.35 6 0.18 mm Hg/mL), EF (69 6 8 to 67 6 7%)
and raised EDV (135 6 19 to 139 6 23 mL) and ESV
(42 6 14 to 47 6 15 mL). Verapamil did not significantly
change heart rate (66 6 11 vs. 65 6 10 min21), SV (93 6
13 vs. 92 6 14 mL), cardiac output (6.1 6 0.92 vs. 5.95 6
0.91 L/min), mean arterial resistance (1271 6 182 vs.
1269 6 209 dyneszseczcom25) or peak filling rate/EDV
(PFREDV, 2.99 6 0.72 vs. 2.87 6 0.59 sec
21).
Hemodynamic responses to intravenous verapamil
during exercise. All subjects achieved 90% predicted heart
rate and/or peak VO2 plateau. Despite initial cardiodepres-
sion from verapamil reflected by reduced PWRmax/EDV
and EF and higher ESV, exercise reserve was similar in both
treatment and saline control studies (Fig. 2, Table 2).
Arterial load was lower throughout exercise (total peripheral
resistance:29%, Ea:27%), whereas EDV and SV were
significantly increased (Fig. 2). Improved cardiac output and
EDV was not accompanied by enhanced diastolic filling, as
verapamil tended to lower PFREDV during exercise (p 5
0.08). Systolic pressure rose similarly during exercise in both
studies. Cardiac output was slightly greater with verapamil
(16% averaged over exercise, Table 2, p , 0.05) despite
slightly slower heart rates (24%, p , 0.05).
Effect of intravenous verapamil on exercise tolerance.
Hemodynamic differences during exercise were accompa-
nied by significant improvement in aerobic exercise perfor-
mance. Exercise duration prior to achieving the AT in-
creased from 260 6 129 to 387 6 176 s (143.4 6 16%, p 5
0.007) with verapamil, and V˙O2 at this time rose from
11.2 6 2.8 to 12.5 6 3.8 mL/min/kg (113.2 6 4.6%, p 5
0.018). Total exercise time increased modestly from 803 6
300 to 845 6 293 sec (15.8 6 2.8%, p 5 0.06) whereas
maximal V˙O2 remained unchanged (12 6 3%, p 5 NS).
Subgroup analysis. While PFREDV did not significantly
change with verapamil in the total study group, individual
responses varied according to baseline value. Control sub-
jects with slower early diastolic filling displayed increases
with verapamil whereas filling rates declined in patients
Figure 1. Effects of intravenous verapamil versus 0.5N NaCl on resting cardiovascular hemodynamics. A. Example showing reduction of
carotid pulse augmentation index (left panel), increases in left ventricular (LV) volumes (middle) and decline in peak ventricular power
(right). Dotted curves are control and solid curves are post verapamil. B. Group data showing effects of verapamil on supine
hemodynamics at rest. Open bars show saline data and solid bars verapamil. * 5 p , 0.05; ** 5 p , 0.01 between studies. Error bars
are SEM.
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with higher resting values. This dependence was given by:
DPFREDV520.353PFREDV,Basal10.93, r 5 0.58, p 5
0.009. To test if improved early filling related to enhanced
exercise capacity, patients were subdivided into those with a
baseline PFREDV #3.0 s
21 (mean 2.4 6 .44, n 5 10) and
those with higher initial values (mean 3.6 6 0.4, n 5 9).
Verapamil increased PFREDV by 11 6 17% in the first
group but reduced it by 212 6 11% in the latter group
Figure 2. Summary hemodynamic data for vascular and ventricular loading between saline and verapamil studies. Open circles denote
saline and solid circles verapamil effects. Pre-D and Post-D indicate before and after infusion under supine rest condition. Pre-EX 5
pre-exercise in upright position; EX1 5 stage-1 exercise (25W); EXmax 5 matched maximal exercise level (100W). There was a consistent
increase in end-diastolic volume (EDV) during exercise. The increase in end-systolic volume (ESV), however, diminished during exercise
to match saline controls. Arterial load (effective arterial elastance Ea and total peripheral resistance TPR) was lower with verapamil while
stroke volume was greater. * 5 p , 0.05; ** 5 p , 0.01 between studies. Error bars are SEM.
Table 2. Systolic Function Response During Exercise in Placebo and
Verapamil-Treated Patients
Preexercise Exercise-25 W Exercise-Max
Cardiac Output Placebo 5.8 6 0.26 10.0 6 0.36 14.1 6 0.91
(L/m) Verapamil 6.43 6 0.24 10.5 6 0.48 15.1 6 0.91
PWRmax/EDV Placebo 7.13 6 0.34 9.3 6 0.49 14.7 6 0.98
(watts/mLz102) Verapamil 6.65 6 0.26 9.3 6 0.58 14.1 6 0.82
Ejection Fraction Placebo 67 6 2 72 6 2 76 6 2
(%) Verapamil 67 6 2 72 6 2 77 6 2
Heart rate Placebo 69.8 6 2.7 96.8 6 3.2 134.1 6 5.9
(beats/min) Verapamil 67.9 6 2.4 92.6 6 4.4 126.8 6 4.8
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(p , 0.003). However, none of the exercise performance
variables significantly differed between subgroups.
In contrast, exercise duration was greater in patients in
whom both ventricular and vascular stiffness declined (re-
flected by PWRmax/EDV, Ea, PWV and AI). In 13 subjects
with reductions in both parameters from verapamil, exercise
duration increased 8.6 6 11.4% whereas the remaining
subjects had less change in duration (20.08 6 12.4%, p ,
0.05 by Mann-Whitney U test).
DISCUSSION
This is the first study to report that acute i.v. verapamil
reduces ventricular-vascular stiffening and improves exercise
capacity in healthy elderly individuals. Enhanced perfor-
mance principally reflected an ability to exercise longer and
reach a higher V˙O2 prior to the anaerobic threshold. There
was far less change in overall exercise duration or maximal
V˙O2. This suggests that exercise efficiency was improved
rather than absolute capacity. Importantly, these changes
occurred without an increase in cardiac per minute-work.
Verapamil lowered preload-corrected PWRmax (a surrogate
for ventricular chamber systolic stiffness) and reduced vas-
cular stiffness as evidenced by AI, PWV and Ea. These data
support the hypothesis that age-related arterial and ventric-
ular stiffening may partially limit exercise performance even
in healthy individuals and that this capacity can improve
from interventions that diminish this stiffening.
Comparison with prior studies. Prior studies regarding
the effects of verapamil on cardiac function and exercise
capacity in nonhypertrophied hearts have mostly employed
oral therapy and highlighted influences on diastolic filling.
For example, Arrighi et al. (26) administered verapamil for
3 to 4 days to middle-aged and older individuals and found
enhanced early diastolic filling whereas this was not ob-
served in younger subjects. That such changes might trans-
late into better exercise capacity was suggested by Petrella et
al. (27) who compared acute (4-h) to chronic (12-week)
effects of oral verapamil in normotensive and hypertensive
elderly subjects. They also observed enhanced diastolic
filling (i.e., reduced isovolumic relaxation time, increased
E:A ratio) associated with higher maximal V˙O2 in both
groups. Interestingly, similar results were achieved with
acute and chronic treatment. Setaro et al. (28) treated
elderly patients with symptomatic heart failure, EF . 45%
and abnormal baseline PFREDV (,2.5) with five weeks of
oral verapamil. They reported a 30% rise in PFREDV and
33% increase in exercise duration.
Our study demonstrates that exercise performance can be
enhanced by even acute i.v. verapamil in elderly individuals,
and that this response does not require increasing early
diastolic filling rates. The lack of an overall change in
PFREDV likely reflected heterogeneity of basal values in our
study group, consistent with prior data (26). Acute i.v.
verapamil also induces more pronounced systolic cardiode-
pression (9) and can have variable effects on relaxation (29)
and thus, early peak filling while arterial load reduction may
be less pronounced. This is consistent with the finding that
pulsatile load, rather than mean resistive load, was mainly
lowered by i.v. verapamil at baseline while contractility
indexed by PWRmax/EDV fell approximately 10%.
Ventricular-vascular stiffening. By lowering both vascular
and ventricular systolic stiffness, verapamil may facilitate
cardiac-arterial interaction, increasing functional reserve by
providing more effective transfer of blood from the heart to
periphery. It seems remarkable that the changes in both
ventricular and vascular stiffnesses by verapamil were mod-
est, yet improvement in aerobic exercise capacity was sub-
stantial. However, when volume is transferred into or out of
stiff chambers there are correspondingly greater changes in
accompanying pressures. Increasing cardiac SV during ex-
ercise would therefore be associated with a greater rise in
arterial systolic pressure, and, in a closed-system, this can
feedback and amplify inhibition of net cardiac ejection.
With verapamil, both PWRmax/EDV declined and ESV
increased, yet they reached similar values at peak exercise as
with saline controls, suggesting increased reserve. Such
recovery during exercise of basal contractile depression from
verapamil has been previously proposed (30) but never as
directly shown as in the present study employing cardiac-
specific power indexes.
Exercise-induced increases in contractile function are
thought to decline in aged hearts (7). This is thought to be
partly due to lower beta-adrenergic responses, but it could
also stem from age-dependent changes in basal ventricular
end-systolic stiffness (Ees) (6). Since acute contractile re-
serve is linked to further increases in Ees (i.e., increasing
slope of the end-systolic pressure-volume relation [31]), a
higher baseline value of Ees limits further change and thus
systolic reserve. By lowering basal contractile function but
not inhibiting increases during exercise, verapamil may
restore some of this reserve.
Verapamil also reduced effective ventricular afterload (Ea)
during exercise due both to a decline in heart rate and fall in
pulsatile and resistive vascular loading. This further en-
hanced cardiac ejection. Our hypothesis that the major
cardiovascular effect from i.v. verapamil was more effective
cardiac output transfer (with similar total cardiac per min-
work) is supported by the type of exercise changes observed,
i.e., aerobic exercise duration and V˙O2. Prior studies per-
formed in younger patients (mean age 52 years) treated
for '1 month with oral verapamil have also displayed
reduced heart rates and arterial load during exercise similar
to that observed in the present study yet, without any
improvement in exercise performance. The effects of vera-
pamil on improving ventricular-arterial interaction likely
depend upon the baseline state (i.e., age-dependent), as was
the case for its effects on PFREDV in the present and earlier
studies (26).
Methodological limitations. Ventricular end-systolic
stiffness (Ees) was not directly measured as there are no
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current methods to do this noninvasively during exercise.
PWRmax/EDV was used as it is measurable during exercise,
minimally load-dependent (32), and prior studies have
shown that relative changes correlate with Ees (20,21) with
the data including effects from i.v. verapamil (20).
Effective arterial elastance was based on an estimate of Pes
which, while validated at rest and with preload reduction in
patients of varying ages (18), nonetheless has not be verified
during exercise. Effective arterial elastance has been re-
ported to decline in younger individuals undergoing supine
exercise (33) whereas it rose in the present study. This may
reflect differences in systolic pressure augmentation during
exercise in older versus younger individuals, faster heart
rates with upright versus supine exercise and methodologic
differences from using dicrotic notch pressure to estimate
Pes.
Clinically occult coronary artery disease is a concern for
any investigation of asymptomatic elderly individuals in
whom invasive coronary arteriography cannot be justified.
Beneficial effects of verapamil on exercise tolerance in
patients with coronary artery disease are well known (34–
36). We cannot entirely rule this factor out, although we did
identify several patients with silent ECG changes associated
with wall motion abnormalities during the initial stress
testing, and these subjects were excluded from further
testing and analysis. None of the remaining patients dem-
onstrated these changes.
Conclusions. We demonstrated that aerobic exercise ca-
pacity is acutely enhanced in elderly healthy individuals by
intravenous verapamil. The dose of verapamil principally
lowered basal pulsatile vascular load and ventricular systolic
contractile function—reflecting reductions of systolic ven-
tricular and vascular stiffening. Such changes may improve
the functional coupling of the heart with the systemic
vascular system, enhancing reserve capacity. While this
study was performed in healthy individuals, the results may
apply to those with baseline exertional intolerance. Heart
failure symptoms in the elderly are often associated with
preserved systolic function (37), and vascular stiffening is
well-documented in elderly heart failure patients (38).
Combined vascular and ventricular-systolic stiffening would
further constrain reserve function. Reducing ventricular-
vascular stiffening may therefore be a logical therapeutic
target, particularly in elderly patients with limited exertional
capacity.
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